Jim Wiltsee

Jim Wiltsee is a managing director in the firm’s healthcare group, with a particular focus on the life sciences sector.

Mr. Wiltsee has advised Morphic on its sale to Eli Lilly; Merck on its acquisition of Harpoon Therapeutics; Interius on its sales to Kite (Gilead); MeiraGTx on the RPGR asset sale back to J&J; Editas on the divestment of its oncology cell therapy platform to Shoreline Biosciences; the ad hoc group of first-lien term lenders for Mallinckrodt’s chapter 11 restructuring; Owens & Minor on its acquisition of Halyard Health; and Blue River PetCare on its sale to Partners Group. Mr. Wiltsee has been involved in over 15 IPOs offerings and 50-plus follow-on equity offerings.

Prior to joining Evercore, Mr. Wiltsee was in investment banking at BofA Merrill Lynch and Piper Sandler advising companies in the healthcare sector. Mr. Wiltsee began his career as a healthcare management consultant.

Mr. Wiltsee earned a B.A. from Haverford College and an MBA from New York University’s Stern School of Business.